HIGHLIGHTS
- who: Martin Vališ from the (UNIVERSITY) have published the paper: Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy, in the Journal: (JOURNAL)
- what: The aim of this is to present a of a 37-year-old female patient with bronchial asthma and no other medical history whose disease activity required switching from dimethyl fumarate to fingolimod then to alemtuzumab and finally to presentation:
SUMMARY
Multiple_sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system, characterised by a very broad heterogeneity in terms of clinical features, genetics . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.